October 2022
Author Information
Braggio DA (1, 2), C de Faria FC (1, 2), Koller D (1, 2), Jin F (3), Zewdu A (1, 2), Lopez G (1, 2), Batte K (1, 2), Casadei L (1, 2), Welliver M (3), Horrigan SK (4), Han R (4), Larson JL (4), Strohecker AM (2, 5, 6), Pollock RE (1, 2).
(1) Program in Translational Therapeutics, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States of America. (2) Department of Surgery, The Ohio State University, Columbus, OH, United States of America. (3) Department of Radiation Oncology, The Ohio State University, Columbus, OH, United States of America. (4) Iterion Therapeutics, INC., Houston, TX, United States of America. (5) Program in Molecular Biology and Cancer Genetics, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States of America. (6) Department of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH, United States of America.
Publication
PLoS One
© Desmoid Tumor Research Foundation (DTRF) | c/o CliftonLarsonAllen LLP, 50 Tice Blvd, Suite 175, Woodcliff Lake, NJ 07677